Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 88 citing articles:

Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System
Julio A. Lamprea‐Montealegre, Erin Madden, Sri Lekha Tummalapalli, et al.
JAMA (2022) Vol. 328, Iss. 9, pp. 861-861
Open Access | Times Cited: 73
Predicting and preventing heart failure in type 2 diabetes
Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 8, pp. 607-624
Closed Access | Times Cited: 35
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
Susanne B. Nicholas, Kenn B. Daratha, Radica Z. Alicic, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2970-2979
Open Access | Times Cited: 35
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
Utibe R. Essien, Balvindar Singh, Gretchen Swabe, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2316290-e2316290
Open Access | Times Cited: 23
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD
L. Parker Gregg, David J. Ramsey, Julia M. Akeroyd, et al.
American Journal of Kidney Diseases (2023) Vol. 82, Iss. 1, pp. 53-62.e1
Open Access | Times Cited: 22
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Luis A. Rodríguez, Holly Finertie, Romain Neugebauer, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100759-100759
Open Access | Times Cited: 8
Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
Min-Jia Cao, Tingting Liang, Li Xu, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
Sok Cin Tye, Niels Jongs, Steven G. Coca, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 33
Practical considerations for the use of SGLT‐2 inhibitors in the Asia–Pacific countries—An expert consensus statement
Adrian Liew, Aida Lydia, Bien J. Matawaran, et al.
Nephrology (2023) Vol. 28, Iss. 8, pp. 415-424
Open Access | Times Cited: 17
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease
Aliza Hussain, David J. Ramsey, Michelle Lee, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 8, pp. 933-942
Open Access | Times Cited: 16
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
Wei‐Han Chen, Yujia Li, Lanting Yang, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0297208-e0297208
Open Access | Times Cited: 6
Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials
Anastasia Adamou, Fotios Barkas, Haralampos Milionis, et al.
International Journal of Stroke (2024) Vol. 19, Iss. 8, pp. 876-887
Closed Access | Times Cited: 6
Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease
Julio A. Lamprea‐Montealegre, Erin Madden, Sri Lekha Tummalapalli, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 2900-2906
Open Access | Times Cited: 27
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Jung‐Im Shin, Yunwen Xu, Alex R. Chang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 683-693
Closed Access | Times Cited: 5
Comparing demographic/clinical characteristics, health care resource utilization, and costs among patients with type 2 diabetes and established atherosclerotic cardiovascular disease with and without the use of cardioprotective medications
Tyler J. Dunn, Yiwen Cao, Lin Xie, et al.
Journal of Managed Care & Specialty Pharmacy (2025), pp. 1-10
Closed Access
Prescription Patterns for GLP-1 Receptor Agonists and SGLT2 Inhibitors by Physicians’ Years in Practice
Kosuke Inoue, Dhruv S. Kazi, Muthiah Vaduganathan, et al.
Journal of General Internal Medicine (2025)
Closed Access
Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study
Rozalina G. McCoy, Jonathan L. Vandergrift, Bradley M. Gray
Diabetes Research and Clinical Practice (2025) Vol. 221, pp. 112039-112039
Open Access
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
Nancy Haff, Daniel M. Horn, Gauri Bhatkhande, et al.
American Heart Journal (2025)
Closed Access
Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
Chutintorn Sriphrapradang, Ammarin Thakkinstian, Ratiporn Chinthammit, et al.
Journal of Diabetes Investigation (2025)
Open Access
Population Health Management for Improving Kidney Health Outcomes
Manisha Jhamb, Jane O. Schell, Melanie R. Weltman, et al.
American Journal of Kidney Diseases (2025)
Open Access
Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention
Shira Yun, Kathryn M. Hurren, Rob Holleman, et al.
BMC Primary Care (2025) Vol. 26, Iss. 1
Open Access
The Effectiveness of an Electronic Decision Support Algorithm to Optimize Recommendations of SGLT2i and GLP-1RA in Patients with Type 2 Diabetes upon Discharge from Internal Medicine Wards
Irit Ayalon‐Dangur, E Jaffe, Alon Grossman, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2170-2170
Open Access
Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service—A registry study
Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, et al.
Diabetic Medicine (2025)
Open Access
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
Daniel V. O’Hara, Meg Jardine
Diabetes Obesity and Metabolism (2025)
Open Access
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
Radhika Nair, Reema Mody, Maria Yu, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 11-12, pp. 1921-1932
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top